Indeed, this strategy may prove more effective by targeting distinct biological functions of cancer cells, such as DNA damage checkpoints (with SMYD3i) and cancer metabolism (with compounds targeting the AMPK/mTOR axis). Here, PRKAA2 is linked to cancer.